Stabilized iRGD modification enhances NY-ESO-1 TCR-T infiltration in solid tumors and synergizes with PD-1 blockade.

Cancer Immunol Immunother · 2025 · PMC12125417 · PMID 40445421

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

S6a, d and g), the iRGD-NY-ESO-1 TCR-T group retained higher DiR signal intensity than the other two groups, though this difference did not reach statistical significance (Fig.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.